A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colorectal Cancer Microsatellite Stable (MSS)
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Non - Small Cell Lung Cancer NSCLC
- Ovarian Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Renal Cell Carcinoma (RCC)
- Triple Negative Breast Cancer (TNBC)
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03549000
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Get Well Soon